Sie sind auf Seite 1von 33

DRUG & STRENGTH

(Storage Prior to Use,


Manufacturer, Presevative
Status)
Aldesleukin
22 million IU
(1.3 mg)
(Chiron)
(F)(PFL)
no preservative1

Alemtuzumab
30 mg/3 mL
(Schering/Ilex)
(F)(PFL)
do not shake
no preservative5
Amifostine
500 mg
(MedImmune)
(RT)
no preservative10

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

do not shake; roll


to reconstitute1

18 million IU/mL1
(1.1 mg/mL)

48 h F, RT1

1.2 mL SWI only1

N/A

10 mg/mL
9.7 mL NS only10

48 h F, RT1

- cytotoxic3
- overfill not known
- do not filter
- nonvesicant4
- latex** content
not determined

SC syringe7

8 h F or RT6

100 mL NS or D5W5

8 h F or RT6

- cytotoxic3
- do not shake6
- protect from light6
- nonvesicant8
- latex-free9

2550 mL* NS only10

540 mg/mL:
24 h F,10 5 h RT

3070 mcg/mL1
50 mL D5W only1
< 30 mcg/mL: dilute
only in D5W that
contains human
albumin 0.1%2

use 5 micron filter to


withdraw drug from
ampoule6

discard unused
portion5

50 mg/mL10

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

24 h F, 5 h RT10

Special
Precautions/Notes

1/33

- noncytotoxic10
- discard cloudy
solution2
- overfill not known
- nonvesicant4
- latex** content
not determined

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Amsacrine
75 mg/1.5 mL
(Pfizer)
(RT)
no preservative1

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

glass syringes
preferred during
reconstitution
- max time in
plastic syringe:
15 min1

5 mg/mL1

24 h RT1

500 mL D5W only1


glass container

72 h F, 24 h RT1

2500 units/mL13

24 h F13

syringe13

14 d F13

Special
Precautions/Notes

- cytotoxic3
- overfill not known
- vesicant11
- contains latex**12

13.5 mL supplied
diluent1
transfer 1.5mL
from ampoule
into the diluent
vial
L-Asparaginase13
(asparaginase E. coli)
10,000 units
(OPi)
(F)

do not shake; roll


to reconstitute1,2
4 mL SWI13

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

2/33

- cytotoxic3
- overfill14
- nonvesicant11
- latex-free**9

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
no preservative14

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

Intradermal
test2:
Reconstitute
with 5 mL
SWI to give
2000
units/mL
Transfer 0.1
mL to 10 mL
vial (or 12 mL
syringe)
Add 9.9 mL
SWI roll to
dissolve to
give 20
units/mL
2 unit test
dose = 0.1
mL
(Note: the rest of
the reconstituted
vial has a
concentration of
2000 units/mL)

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

50 mL* NS or
15,16
D5W

14 d F, 15,16 2 d RT16,17

3/33

Special
Precautions/Notes

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
BCG
81 mg
(Aventis Pasteur)
(F)(PFL)
preservative1

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

do not shake; roll


to reconstitute18

10.5 8.7108
CFU/vial (Connaught
strain)1

2 h F, RT1

50 mL NS1

2 h F or RT after
reconstitution1

- cytotoxic3
- overfill not known
- protect from
light18
- nonvesicant11
- latex** content
not determined

1-8108 CFU/vial
(TICE strain)1

2 h F19

transfer from vial to


50 mL syringe, rinse
vial with another 1
mL NS. Add rinse to
50 mL syinge. QS
syringe to 50 mL with
NS1

2 h F after
reconstitution19

- cytotoxic3
- overfill not known
- protect from
light19
- do not filter
- nonvesicant11
- latex-free**9

25 mg/mL20

discard unused
portion20

100 mL NS only20

48 h F, RT17,20

- cytotoxic3
- do not shake20
- nonvesicant11
- latex** content
not determined

3 mL supplied
diluent1
record time of
reconstitution

BCG
(Organon)
(F)(PFL)
no preservative1

do not shake; roll


to reconstitute19
1 mL NS1
record time of
reconstitution

Bevacizumab
100 mg/4 mL
400 mg/16 mL
(Roche)
(F)(PFL)
do not shake20
no preservative20

N/A

Special
Precautions/Notes

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

4/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Bleomycin
15 IU
(NB: dose in units only)
(Bristol)
(F)
no preservative21
Bleomycin
15 IU
(NB: dose in units only)
(Mayne)
(F)(PFL)22
no preservative1
Bortezomib
3.5 mg
(Millennium)
(RT)(PFL)
no preservative25
Busulfan
60 mg/10 mL
(Orphan Medical)
(F)
no preservative29

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

Special
Precautions/Notes

6 mL* NS21

2.5* IU/mL

48 h F21

50 mL* NS21

NS: 24 h RT21

- cytotoxic3
- overfill not known
- nonvesicant11
- latex** content
not determined

6 mL* NS or
SWI22

2.5* IU/mL22

48 h F, 24 h RT

50 mL* NS, SWI22

24 h RT23

- cytotoxic3
- overfill not known
- nonvesicant11
- latex-free24

3.5 mL NS25

1 mg/mL25

2d RT26,27

syringe25

8 h RT28

- cytotoxic3
- overfill not known
- irritant4
- latex** content
not determined

N/A

use 5-micron nylon


filter provided with
ampoule to withdraw
drug29

discard unused
portion29

NS or D5W (dilute in
volume 10 times the
busulfan volume to ~
0.5 mg/mL)29

12 h F: NS29
8 h RT: NS, D5W

- cytotoxic3
- vesicant11
- latex** content
not determined

discard unused
portion30

may be further
diluted up to 0.3-2
mg/mL

48 h F30

- cytotoxic3
- nonvesicant11
- latex** content
not determined

22

6 mg/mL29
Carboplatin
50 mg/5 mL
150 mg/15 mL
450 mg/45 mL
(Mayne Pharma)
(RT)(PFL)
no preservative30

N/A

10 mg/mL30

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

250 mL* NS, D5W2,30

5/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Carboplatin
50 mg/5 mL
150 mg/15 mL
450 mg/45 mL
(Novopharm)
(RT)(PFL)
no preservative31
Carmustine
100 mg
(Bristol Labs)
(F)
no preservative33

Cetuximab
100 mg/50 mL
(BMS)
(F)
do not dilute35
do not shake35
no preservative35

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

10 mg/mL31

8 h RT31

8 h RT31

may be further diluted


to 0.5 mg/mL31,32

Special
Precautions/Notes

- cytotoxic3
- nonvesicant11
- latex-free**9

250 mL* NS,


D5W2,31,32
3 mL diluent
(supplied)33

3.3 mg/mL in 10%


ethanol33

24 h F, 8 h RT 33

500 mL NS or D5W33

diluent to reach
RT, then dissolve
drug with 3 mL
diluent;
add 27 mL SWI33

N/A

glass,33 or polyolefin
container2

33

24 h F: in glass, or
polyolefin container2
use within 4 hours of
reconstitution RT16,33

2 mg/mL35

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

discard unused
portion35

syringe35

12 h F, 8 h RT35

6/33

- cytotoxic3
- do not use if
product has oily
droplets33
- overfill not known
- vesicant11
- latex** in diluent
stopper9,34
- no latex** in
product stopper or
drug product34
- cytotoxic3
- do not shake35
- use 0.22 micron
in-line filter to
administer
- nonvesicant 4
- latex** content
not determined

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)

Cisplatin
10 mg/10 mL
50 mg/50 mL
100 mg/100mL
(Mayne)
(RT)(PFL)
no preservative36

Cladribine
10 mg/10 mL
(Janssen-Ortho)
(F)(PFL)
no preservative40

Clodronate
300 mg/10 mL
(Oryx)
(RT)
no preservative41

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

1 mg/mL36

48 h RT37

Special
Precautions/Notes

sterile evacuated
container e.g., glass
bottle, polyolefin bag,
ethylene vinyl acetate
bag, DEHP
plasticized PVC bag,
or PVC bag35

12 h F, 8 h RT,35

< 60 mg: 100 NS*


> 60 mg: 250 NS*

48 h RT37

- cytotoxic3
- irritant11
- latex stoppers39

500 or 1000 mL* NS,


D5-NS, D5-1/2S; D5NS with mannitol; D51/2S with
mannitol36,38; D5W1/3S with mannitol36
N/A

1 mg/mL40

discard unused
portion40

500 mL NS only40

24 h RT40

- cytotoxic3
- shake vigorously
to dissolve any
precipitates from
refrigeration2
- nonvesicant11
- protect from
light40
- latex-free**9

N/A

30 mg/mL

discard unused
portion41

500 mL NS or D5W41

12 h RT41

- noncytotoxic
- nonvesicant11
- latex** content
not determined

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

7/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Cyclophosphamide
non-lyophilized
1000 mg
2000 mg
(BMS)
(RT)
no preservative42

Cyclophosphamide
200 mg
500 mg
1000 mg
2000 mg
(Baxter)
(RT)(PFL)
no preservative43
Cytarabine
100 mg/1 mL
500 mg/5mL
1000 mg/10mL
2000 mg/20mL
(Mayne)
(RT)
no preservative46

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

SWI42

20 mg/mL42

48 h F, 24 h
RT16,42

1000 mg: 50 mL
2000 mg: 100 mL

< 1 g: 100 NS*


> 1 g: 250 NS*
high dose in BMT:
may need 500 NS*

6 d F, 24 h RT42

Special
Precautions/Notes

- cytotoxic3
- overfill not known
- nonvesicant11
- latex-free**9,34

NS,2 D5W, D5NS,


D5, Ringers,
Lactated Ringers,
Sodium Chloride
0.45%, Sodium
Lactate42
NS43

20 mg/mL43

48 h F,27,43,44 24
RT45

200 mg: 10 mL
500 mg: 25 mL
1000 mg: 50 mL
2000 mg: 100
mL43
N/A

< 1 g: 100 NS*


> 1 g: 250 NS*
high dose in BMT:
may need 500 NS*

48 h F,27,43 24 h RT43

- cytotoxic3
- nonvesicant11
- latex** content
not determined

72 h F, 24 h RT from
initial vial puncture46

- cytotoxic3
- nonvesicant11
- latex stopper**48

NS,2 D5W, D5NS43


100 mg/mL46

record time of
punture

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

24 h RT46

0.1-0.8 mg/mL47
100 mL* NS, Water
for Injection, D5W,
Lactated Ringers

8/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Cytarabine
IT injection46:
100 mg/1 mL
500 mg/5 mL
1000 mg/10mL
2000 mg/20mL
(Mayne)
(RT)
no preservative46

Cytarabine
SC injection:
100 mg
1000 mg
vial
(Pfizer)
(RT)(PFL)
no preservative1
Cytarabine
SC injection:
100 mg
500 mg
1000 mg
2000 mg
vial
(Novopharm)
(RT)(PFL)
no preservative31

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

100 mg/mL46

24 h RT46

diluents containing
preservatives should
NOT be used for
intrathecal
administration46

use within 4 hours of


initial puncture2,16

- cytotoxic3
- auxiliary label50:
IT
- label to include
route in full (i.e.,
INTRATHECAL
injection) atttached
to both syringe and
outer ziplock bag50
- nonvesicant11
- latex stopper**48

qs to 6 mL with
preservative free
NS49

100 mg: 5 mL
BWI1

100 mg:
20 mg/mL1

1 g: 10 mL BWI1

1000 mg:
100 mg/mL1

BWI31

100 mg: 20 mg/mL


500 mg: 50 mg/mL
1000 mg: 100 mg/mL
2000 mg: 100 mg/mL

100 mg: 5 mL
500 mg: 10 mL
1000 mg: 10 mL
2000 mg: 20 mL

48 h RT51

syringe

14 d F, 48 h RT51

- cytotoxic3
- for high dose
use, do not use
diluent containing
benzyl alcohol31
-overfill not known
- nonvesicant11
- latex-free**9

48 h F, RT16,31

syringe

14 d F, 48 h RT2,16,17

- cytotoxic3
- for high dose
use, do not use
diluent containing
benzyl alcohol31
- overfill not known
- nonvesicant11
- latex** content
not determined

31

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

Special
Precautions/Notes

9/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Dacarbazine
200 mg
600 mg
(Mayne)
(F)(PFL)
no preservative52

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

200 mg: 19.7 mL


SWI52
600 mg: 59.1 mL
SWI

10 mg/mL52

48 h F,16,53 8 h
RT53
(PFL)54

0.193.0 mg/mL52

24 h F52

- cytotoxic3
- protect from
light54
- no overfill54
- irritant11
- latex stopper**9,48

syringe52

24 h F, RT16,56

infusion: 50 mL*
D5W, NS2,16,53

24 h F, RT56

- cytotoxic3
- do not filter2
- overfill not known
- vesicant11
- latex-free**57

100-250 mL
NS or D5W2

48 h F, 24 h RT31

empty viaflex bag59

6 h RT60

500 mL* NS or D5W

(may use
reconstitution
device)
Dactinomycin
0.5 mg
(Merck Frost)
(RT)(PFL)
no preservative55

Daunorubicin
20 mg
(Novopharm)
(RT)(PFL)
no preservative31
Dexrazoxane
250 mg
500 mg
(Pfizer)
(RT)
no preservative59

1.1 mL SWI55

4 mL SWI31

0.5 mg/mL55
(500 mcg/mL)

5 mg/mL31

24 h F, RT56

24 h RT, 48 h F31
(PFL)31

supplied diluent
59
:
250 mg: 25 mL
500 mg: 50 mL

10 mg/mL59

6 h F59

(may use
reconstitution
device)

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

Special
Precautions/Notes

10/33

- cytotoxic3
- overfill not known
- vesicant11
- latex-free**9,58
- cytotoxic61
- no overfill61
- nonvesicant4
- latex-free**9,62

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Docetaxel
20 mg/0.5 mL
80 mg/2 mL
(Aventis)
(PFL)
no preservative63

Doxorubicin
10 mg
50 mg
150 mg
(Mayne)
(RT)(PFL)
no preservative64
Doxorubicin
10 mg/5 mL
20 mg/10 mL
50 mg/25 mL
200 mg/100 mL
(Novopharm)
(F)(PFL)
no preservative67

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

supplied diluent :
- if vials were
refrigerated, allow
to warm for 5 min
at RT. Withdraw
entire contents of
the diluent and
mix by repeated
inversions for 45
sec DO NOT
SHAKE. - Let sit
63
for 5 minutes.

10 mg/mL63

NS, SWI, D5W64


(NS reconstitution
takes longer)
10 mg: 5 mL
50 mg: 25 mL
150 mg: 75 mL

2 mg/mL64

N/A

2 mg/mL

8 h F, RT63

0.30.74 mg/mL

4 h F, RT63

(e.g., 250 mL NS or
D5W)63

48 h F, 24 h RT,
16,64

syringe64

48 h F, 24 h RT16,65

0.22 mg/mL66

48 h F, 24 h RT16,66

Special
Precautions/Notes

- cytotoxic3
- non-PVC bag
and tubing only63
- overfill63
- irritant11
- latex-free**9

- cytotoxic3
- overfill not known
- vesicant11
- latex stopper**9,48

100 mL* NS64

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

8 h RT67

syringe67

48 h F, 24 h RT67

11/33

- cytotoxic3
- overfill not known
- vesicant11
- latex** content
not determined

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Doxorubicin
Pegylated Liposomal
20 mg/10 mL
50 mg/25 mL
(Schering)
(F)
no preservative68
Epirubicin
10 mg/5 mL
50 mg/25 mL
200 mg/100 mL
(Pfizer)
(F)(PFL)
no preservative69
Etoposide
100 mg/5 mL
500 mg/25 mL
1000 mg/50 mL
(BMS)
(RT)
preservative70

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

2 mg/mL68

discard unused
portion68

24 h F68

- cytotoxic3
- do not filter68
- vesicant11
- latex-free**9

syringe69

48 h F, 24 h RT from
initial vial puncture69

- cytotoxic3
- vesicant11
- latex-free**9

100 mL* NS or D5W2

2 d F, RT: NS or
D5W16,37

0.2 0.4 mg/mL70

0.2 mg/mL: 96 h RT70


0.4 mg/mL: 24 h RT70

< 90 mg: 250 mL


D5W only68
90 mg: 500mL D5W
only

N/A

2 mg/mL69

8 h F, RT69

record time of
puncture

N/A

20 mg/mL70

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

14 h RT16,71

Special
Precautions/Notes

500 mL* NS or
D5W70

12/33

- cytotoxic3
- use non-PVC bag
and tubing only
- irritant11
- latex** content
not determined

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Etoposide
100 mg/5 mL
200 mg/10 mL
500 mg/25 mL
1000 mg/50 mL
(Novopharm)
(RT)(PFL)
no preservative72

Fludarabine
50 mg
(Berlex)
(F)
no preservative73

Fluorouracil
5000 mg/100 mL
(Mayne)
(RT)(PFL)
no preservative74

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

20 mg/mL72

discard unused
portion72

max. 0.4 mg/mL72

4 h RT27,72

- cytotoxic3
- use non-PVC bag
and tubing only
- irritant11
- latex** content
not determined

48 h F, RT16,37

- cytotoxic3
-overfill not known
- nonvesicant11
- latex-free**9

syringe16

48 h RT16,17,48

may be further diluted


to 2 mg/mL in
D5W48,74

24 h RT48,74

- cytotoxic3
- irritant11
- latex-free**54

500 mL* NS or
D5W72

2 mL SWI73

25 mg/mL73

48 h F or RT16,37

may be further diluted


to 1 mg/mL73
100 mL* NS or
D5W73

N/A

50 mg/mL74

8 h RT48,74

50-1000 mL* D5W

CIVI: ambulatory
pump48

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

Special
Precautions/Notes

complete within 8
2,75,76
d

13/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Gemcitabine
200 mg
1000 m g
(Eli-Lilly)
(RT)
no preservative77

Idarubicin
5 mg
10 mg
(Pfizer)
(RT)(PFL)
no preservative79

Ifosfamide
1000 m g
3000 mg
(Baxter)
(RT)2
no preservative82

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

200 mg: 5 mL NS
1000 mg: 25 mL
NS77

38 mg/mL77

48 h RT78

(may use
reconstitution
device)
vial under
negative
pressure79

Interferon Alfa -2b


25 million IU/2.5 mL
(Schering)
(F)(or up to 7 days at

48 h RT16,78

0.110 mg/mL77,78

48 h F, RT16,78

- cytotoxic3
- no overfill78
- nonvesicant11
- latex-free**9,78

250 mL NS*
1 mg/mL79

48 h F,79 24 h
RT,
(PFL)79

syringe

48 h F,79,80 24 h RT16
(PFL)79

- cytotoxic3
- overfill not known
- vesicant11
- latex-free**81

50 mg/mL82

72 h F82

0.620 mg/mL82

72 h F82

5001000 mL* NS,


D5W, D5-NS,
D5-1/2NS, Lactated
Ringers2,82

24 h F, RT when
mixed with mesna2

- cytotoxic3
- overfill not known
- nonvesicant11
- latex-free**9

5 mg: 5 mL SWI
10 mg: 10 mL
SWI79
1000 mg: 20 mL
SWI82
3000 mg: 60 mL
SWI
shake well

Interferon Alfa -2b


18 million IU/3 mL
(Schering)
(F)(or up to 7 days at
RT before use)
no preservative83

syringe77

Special
Precautions/Notes

N/A

6 million IU/mL83

48 h F16,83

D5W or Lactated
Ringers when mixed

syringe83

2 d F16,84

0.3 million IU/mL83

24 h F, RT84

- cytotoxic3
- overfill83
- nonvesicant11
- latex-free**9,84

50 mL NS83
N/A

10 million IU/mL83

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

48 h F16,83

syringe83

2 d F16,84

14/33

- cytotoxic3
- overfill83
- nonvesicant11

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
RT before use)
no preservative83

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

0.3 million IU/mL

83

84

Special
Precautions/Notes
- latex-free**9,84

24 h F, RT

50 mL NS83
Interferon Alfa -2b
10 million IU
(Schering)
(F)
no preservative83

1 mL supplied
diluent (SWI) 83

10 million IU/mL83

24 h F83

do not shake; roll


to reconstitute83

syringe83

24 h F, RT84

> 0.1 million IU/mL85

48 h RT2,16

- cytotoxic3
- overfill83
-nonvesicant11
- latex-free**9,84

100 mL NS86

1 mL BWI83

48 h F, RT16,83

do not shake; roll


to reconstitute83
Interferon Alfa -2b
18 million IU
(Schering)
(F)
no preservative83

1 mL supplied
diluent 83

18 million IU/mL83

24 h F83

do not shake; roll


to reconstitute83

syringe86

14 d F, 48 h RT16,86

100 mL NS86

48 h RT2,16

syringe83

24 h F, RT84

> 0.1 million IU/mL85

48 h RT2,16

100 mL NS86
1 mL BWI83
do not shake; roll
to reconstitute83

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

48 h F, RT16

syringe83

14 d F16,86

100 mL NS86

48 h RT2,16
15/33

- cytotoxic3
- overfill83
- nonvesicant11
- latex-free**9,84

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Irinotecan
40 mg/2 mL
100 mg/5 mL
500 mg/25 mL
(Mayne)
(RT)(PFL)
no preservative87
Irinotecan
40 mg/2 mL
100 mg/5 mL
(Pfizer)
(RT)(PFL)
no preservative89
Leucovorin
50 mg/5 mL
500 mg/50 mL
(Mayne)
(F)(PFL)
no preservative90

Mechlorethamine
10 mg
(Merck)
no preservative92

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

N/A

N/A

do NOT use if
discoloured or
water droplets

20 mg/mL87

20 mg/mL89

10 mg/mL90

1 mg/mL92

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

2 days RT27,88

0.12 2.8 mg/mL87

24 h RT: D5W, NS87

500 mL2 D5W


(preferred), NS87

48 h F: D5W
(PFL)87

0.12 2.8 mg/mL89

24 h RT: D5W, NS89

500 mL2 D5W


(preferred), NS89

48 h F: D5W
(PFL)89

5 mL vial: discard
unused portion90

syringe91

48 h F91

50 mL vial: 8 h F,
RT

may be further diluted


to 0.05 mg/mL90

24 h RT90: NS, D5W,


Lactated Ringers,
Ringers

50-250 mL* NS,


D5W, Lactated
Ringers, Ringers,
D10W, D5-NS

8 h RT90: D10W, D5NS

discard unused
portion89

use within 4
hours of
reconstitution

syringe92

use within 4 hours of


reconstitution RT16,37,92

16/33

Special
Precautions/Notes

- cytotoxic3
- do NOT
refrigerate if in
NS89
- nonvesicant11
- latex** content
not determined
- cytotoxic3
- do NOT
refrigerate if in
NS89
- nonvesicant11
- latex-free**9
- noncytotoxic
- nonvesicant11
- latex-free**48

- cytotoxic3
- overfill not known
- vesicant11

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability
RT2,80

form in vial before


reconstitution2

100 mL NS2

use within 4 hours of


reconstitution RT16,37,92

Special
Precautions/Notes
- latex** content
not determined

10 mL SWI or
NS92

Medroxyprogesterone
250 mg/5 mL
(Pfizer)
(RT)
preservative1
Medroxyprogesterone
Depo
150 mg/1mL
(Pfizer)
(RT)
preservative1
Melphalan
50 mg
(GSK)
(RT)(PFL)
no preservative93

N/A

50 mg/mL1

use within 4
hours of initial
puncture1,16

syringe: IM only1

use within 4 hours of


initial puncture1,16

- cytotoxic3
- auxiliary label:
shake before use1- nonvesicant4
- latex-free**9

N/A

150 mg/mL1

use within 4
hours of initial
puncture1,16

syringe: IM only1

use within 4 hours of


initial puncture1,16

- cytotoxic3
- auxiliary label:
shake before use1
- nonvesicant4
- latex-free**9

10mL supplied
diluent 93

5 mg/mL93

2 h RT93

0.1 0.45 mg/mL in


NS only

1 h RT from time of
initial reconstitution2

- cytotoxic3
- overfill not known
- vesicant11
- latex-free**94

immediately after
adding diluent,
shake
vigorously93

do NOT
refrigerate

(e.g., >45 mg and <


110 mg in 250 mL
NS)*

record time of
reconstitution

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

17/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Mesna
1000 mg/10mL
(PPC)
(RT)
preservative95

Methotrexate
50 mg/2mL
500 mg/20mL
1 g/40mL
5 g/200mL
(Mayne)
(RT)(PFL)
no preservative52

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

100 mg/mL95

14 d F, RT16,95

> 1mg/mL95

48 h F, 24 h RT95

NS or D5W

N/A

25 mg/mL52

50mg: discard
unused portion52
500mg, 1 g mL, 5
g mL: 8 h F, RT52

syringe

2 d F, RT2,96,97

0.42 mg/mL52

24 h RT52

100 mL*
NS, D5W

Special
Precautions/Notes

- noncytotoxic
- nonvesicant
(diluted)11
- irritant
(undiluted)11
- latex** content
not determined
- cytotoxic3
- for high-dose
regimens (e.g., 1-8
mg/m2 as a single
dose)98-101 use
preservative-free
methotrexate2
- nonvesicant11
- latex-free**48

high dose(e.g., 1-8


mg/m2 as a single
dose)98-101: 5001000
mL*
Methotrexate
IT Injection52:
Only preservative free
methotrexate may be
administered by the
intrathecal route52
20 mg/2mL
(Mayne)
(RT)(PFL)
no preservative52

N/A

10 mg/mL52

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

discard unused
portion52

qs to 6 mL with
preservative free
NS49

use within 4 hours of


initial puncture2,16

18/33

- cytotoxic3
- auxiliary label50:
IT
- label to include
route in full (i.e.,
INTRATHECAL
injection) atttached
to both syringe and
outer ziplock bag50
- nonvesicant11
- latex-free**48

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Methotrexate
50 mg/2mL
500 mg/20mL
(Mayne)
(RT)(PFL)
preservative52

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

25 mg/mL52

24 h F96

syringe

7 d F2,96,97

0.42 mg/mL52

24 h RT52

e.g., 100 mL* NS,


D5W52
Mitomycin
5 mg
20 mg
(Novopharm)
(RT)(PFL)
no preservative31

SWI
5 mg: 10 mL
20 mg: 40 mL

0.5 mg/mL31

48 h F, RT16,31

syringe2,16

(PFL)31

shake well31
0.02-0.04 mg/mL
50 mL* NS, D5W,
sodium lactate
31

Mitomycin
5 mg
20 mg
(BMS)
(RT)(PFL)
no preservative103

14 d F, 48 h RT2,16,17

SWI
5 mg: 10 mL
20 mg: 40 mL

0.5 mg/mL103

48 h F, RT16,103

syringe2

0.020.04 mg/mL

(may use
reconstitution
device)

50 mL* NS, D5W,


sodium lactate103

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

- cytotoxic3
- high-dose
regimen(e.g., 1-8
mg/m2 as a single
dose) 98-101: use
preservative-free
methotrexate2
- nonvesicant11
- latex-free**9,48
- cytotoxic3
- overfill not known
- vesicant11
- latex-free**
(stopper or
product)9,102

3 h RT: D5W
12 h RT: NS
24 h RT: sodium
lactate31
14 d F, 48 h RT2,17

(PFL)31

shake well103

Special
Precautions/Notes

12 h RT: NS
3h: D5W
24 h: sodium lactate103

19/33

- cytotoxic3
- no overfill102
- vesicant11
- latex stopper**9,34

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Mitoxantrone
20 mg/10 mL
25 mg/12.5 mL
(Wyeth)
(RT)(PFL)
no preservative104
Mitoxantrone
20 mg/10mL
(Mayne)
(RT)(PFL)
no preservative105

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

2 mg/mL104

discard unused
portion104

NS, D5W104

24 h RT104

50 mL*

N/A

2 mg/mL105

discard unused
portion105

0.2-0.6 mg/mL53

NS: 24 h F, RT

NS, D5W105

D5W: 72 h F, 24 h
RT105

50 mL*
Octreotide
(Sandostatin)
1000 mcg/5 mL
(Novartis)
(F)(PFL)
preservative1

Octreotide
(Sandostatin)
50 mcg/1 mL
100 mcg/1 mL
500 mcg/1 mL
(Novartis)
(F)(PFL)
no preservative1

N/A

200 mcg/mL1

discard unused
portion106

50200 mL NS1
2,107

Special
Precautions/Notes

- cytotoxic3
- protect from light
- irritant11
- latex** content
not determined
- cytotoxic3
- protect from
light53
- irritant11
- latex-free**9

24 h RT1

- noncytotoxic10
- nonvesicant11
- latex-free**9

24 h RT1

- noncytotoxic10
- nonvesicant11
- latex-free9

SC infusion: adjust
volume to ensure
infusion rate of 25
mcg/h1
N/A

50 mcg/mL
100 mcg/mL
500 mcg/mL1

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

discard unused
portion1

50-100 mL2,107
NS1
SC infusion: adjust
volume to ensure
infusion rate of 25
mcg/h1

20/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Octreotide
(Sandostatin LAR)
10 mg
20 mg
30 mg
(Novartis)
(F)(PFL)1
preservative106

Oxaliplatin
50 mg
100 mg
(Sanofi-Aventis)
(RT)
no preservative108

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

2 mL supplied
diluent

10 mg: 5 mg/mL
20 mg: 10 mg/mL
30 mg: 15 mg/mL

discard unused
portion1

deep intragluteal
administration only1

use within 4 hours of


initial reconstitution1,16

5 mg/mL108

24 h F109

> 0.2 mg/mL

24 h F,108 6 h RT109

gently run 2 mL
down sides of the
vial; do NOT
disturb for 25
min, then swirl
moderately1

SWI, D5W:
50 mg: 10 mL
100 mg: 20 mL
do NOT use NS
or other chloridecontaining
solutions
(degrades)108

250500 mL D5W
do NOT use NS or
other chloridecontining solutions
(degrades)108

(may use
reconstitution
device)

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

21/33

Special
Precautions/Notes

- noncytotoxic10
- do NOT shake
- overfill not known
- nonvesicant11
- latex-free**9

- cytotoxic3
- no overfill
- irritant11
- latex** content
not determined

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Oxaliplatin
50 mg
100 mg
(Mayne)
(RT)
no preservative110

Oxaliplatin
50 mg
100 mg
(Sigmacon)
(RT)
no preservative111

Paclitaxel
30 mg/5 mL
100 mg/16.7 mL
300 mg/50 mL
(Biolyse)
(F) (may store at RT for
2 months)112
no preservative

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

SWI, D5W:
50 mg: 10 mL
100 mg: 20 mL

5 mg/mL110

discard unused
portion110

SWI, D5W:
50 mg: 10 mL
100 mg: 20 mL

- cytotoxic3
- irritant11
- latex** content
not determined

24 h F, 6 h RT111

- cytotoxic3
- irritant11
- latex** content
not determined

do NOT use NS or
other chloridecontining solutions
(degrades)110
5 mg/mL111

24 h F111

500 mL D5W
do NOT use NS or
other chloridecontining solutions
(degrades)111

do NOT use NS
or other chloridecontaining
solutions
(degrades)111
N/A

48 h F110

> 0.2 mg/mL


250 500 mL D5W

do NOT use NS
or other chloridecontaining
solutions
(degrades)110

Special
Precautions/Notes

6 mg/mL112

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

8 h RT112

0.31.2 mg/mL in NS,


D5W112

24 h RT112

(e.g., 1001000 mL)*

22/33

- cytotoxic3
- use non-PVC bag
and tubing with inline filter112
- irritant11
- latex** content
not determined

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Paclitaxel
30 mg/5 mL
100 mg/16.7 mL
300 mg/50 mL
(BMS)
(RT)(PFL)
no preservative113
Pamidronate
30 mg/10 mL
60 mg/10 mL
90 mg/10 mL
(Mayne)
(RT)
no preservative114

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

N/A

6 mg/mL113

3 mg/mL
6 mg/mL
9 mg/mL114

30 mg: 48 h
RT16,113
100 mg: 48 h
RT16,113
300 mg: 24 h

0.31.2 mg/mL in NS,


D5W, D5-NS, D5 in
Ringers113

discard unused
portion114

0.060.36 mg/mL
NS, D5W114

24 h RT113

(e.g.,1001000 mL)*

Special
Precautions/Notes

- cytotoxic3
- irritant11
- use non-PVC and
tubing with in-line
filter113
- latex-free**9

24 h F followed by 24
h RT (total 48 h)114

- noncytotoxic116
- protect from
light114
- nonvesicant4
- latex-free**9

24 h F, RT117

- cytotoxic3
- overfill117
- nonvesicant4
- latex** content
not determined

use within 4 hours of


initial
reconstitution16,119

- noncytotoxic3
- overfill118
- irritant11
- latex-free**9,119

do NOT mix with


calcium containing
solution (e.g.,
Ringers)114
e.g., 250 mL NS115

Pemetrexed
500 mg
(Eli Lilly)
(RT)
no preservative117

Porfimer
15 mg
75 mg
(Axcan)
(RT)(PFL)
no preservative118

20 mL NS117

25 mg/mL117

24 h F, RT117

dilute with NS to total


volume 100 mL78,117
do NOT mix with
calcium containing
solution (e.g.,
Ringers)117

6.6 mL D5W
31.8 mL D5W118

2.5 mg/mL118

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

24 h F
(PFL)118

syringe118

23/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Raltitrexed
2 mg
(AstraZeneca)
(F, RT)(PFL)
no preservative120
Rituximab
100 mg/10 mL
500 mg/50 mL
(Roche)
(F)(PFL)
no preservative62

Streptozocin
1g
(Pfizer)
(F)(PFL)
no preservative121
Teniposide
15 mg/1.5 mL
(Bristol)
preservative1

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

4 mL SWI120

0.5 mg/mL120

24 h F, RT120

50250 mL NS,
D5W120

24 h F, RT120

N/A

10 mg/mL62

discard unused
portion62

14 mg/mL in NS,
D5W)62

24 h F + additional 12
h RT62

Special
Precautions/Notes

- cytotoxic3
- overfill not known
- nonvesicant11
- latex-free**9
- noncytotoxic3
- nonvesicant11
- latex-free**9

(e.g., 500 mg/250


mL, 1000 mg/500
mL)*
9.5mL NS, SWI,
D5W 121

N/A

100 mg/mL121

10 mg/mL1

48 h F,121 24 h
RT

discard unused
portion1

syringe121

48 h F, 24 h RT121

50-500 mL* NS,


D5W, SWI121

48 h F, 24 h RT121

0.1, 0.2, 0.4, or 1


mg/mL in NS or
D5W1

0.1, 0.2, 0.4mg/mL: 24


h RT
1 mg/mL: complete
administration within 4
h1

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

24/33

- cytotoxic3
- overfill not known
- vesicant11
- latex-free**9
- cytotoxic3
- do NOT
refrigerate1
- use non-PVC
equipment1
- irritant11
- latex-free9

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Thiotepa
15 mg
(Bedford)
(F)(PFL)
no preservative122

Thiotepa
IT injection:
15 mg
(Bedford)
(F)(PFL)
no preservative122

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

1.5 mL SWI122

10 mg/mL122

8 h F122

> 50 mL* NS122

use within 4 hours of


initial
reconstitution16,122

- cytotoxic3
- filter through 0.22
micron filter before
administration122
- overfill not known
- nonvesicant11
- latex** content
not determined

diluents
containing
preservatives
should NOT be
used for
intrathecal
administration

2 mg/mL solution2

use
immediately122

qs to 6 mL with
preservative free
NS49

use within 4 hours of


initial
reconstitution16,49,122

- auxiliary label50 :
IT
- label to include
route in full (i.e.,
INTRATHECAL
injection) atttached
to both syringe and
outer ziplock bag50
- cytotoxic3
- filter through 0.22
micron filter before
administration122
- overfill not known
- nonvesicant11
- latex** content
not determined

1 mg/mL123

24 h F, RT123

0.020.5 mg/mL

24 h F, RT123

- cytotoxic3
- overfill not known
- nonvesicant11
- latex-free**9

7.5 mL NS2

Topotecan
4 mg
(GSK)
(RT)(PFL)
no preservative123

Special
Precautions/Notes

4 mL SWI123

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

50100 mL NS,
D5W123

25/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Trastuzumab
440 mg
(Roche)
(F)
preservative124

Vinblastine
10 mg/10 mL
(Mayne)
(F)(PFL)
no preservative24

Vincristine
1 mg/1 mL
2 mg/2 mL
5 mg/5 mL
(Mayne)
(F)(PFL)
no preservative127

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

20 mL supplied
BWI

21 mg/mL124

14 d F76,124

N/A

24 h F, RT124

- noncytotoxic3
- do NOT shake124
- overfill not known
- nonvesicant11
- latex** content
not determined

syringe2,24

48 h F125

100250 mL NS,
D5W126

14 d F: NS17,125

- cytotoxic3
- auxiliary label (for
syringe only):
Warning: FATAL if
given
intrathecally24
- vesicant11
- latex-free**48

syringe: qs to 20 mL
with NS in 30 mL
syringe*

48 h RT, 7 d F2,16,128

do NOT use dextrose


containing
solutions124

swirl vial gently;


allow to stand
undisturbed for 5
min124
N/A

250mL NS124

1 mg/mL24

1 mg/mL 127

24 h F, RT125

8 h F, RT127

- cytotoxic3
- auxiliary label (for
syringe only):
Warning: FATAL if
given intrathecally
127

50 mL* NS, D5W

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

Special
Precautions/Notes

127

24 h F, 6 h RT,

26/33

127

- protect from
light127
- vesicant11
- latex-free**48

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
Vincristine
1 mg/1 mL
2 mg/2 mL
5 mg/5 mL
(Novopharm)
(F)(PFL)
preservative31

Vinorelbine
10 mg/1 mL
50 mg/5 mL
(GSK)
(F)(PFL)
no preservative129

Vinorelbine
10 mg/1 mL
50 mg/5 mL
(Mayne)
(F)(PFL)

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

N/A

1 mg/mL31

14 d F, RT31

syringe: qs to 20 mL
with NS in 30 mL
syringe*

48 h RT, 7 d F2,16,128

Special
Precautions/Notes

- cytotoxic3
- auxiliary label (for
syringe only):
Warning: FATAL if
given intrathecally
31

50 mL* NS, D5W31

72 h F, 24 h RT31

- protect from
light31
- vesicant11
- latex-free**9

N/A

10 mg/mL129

discard unused
portion129

syringe: 1.5 3.0


mg/mL in NS or
D5W129

24 h F, RT129

- cytotoxic3
- auxiliary label (for
syringe only):
Warning: FATAL if
given
intrathecally129
- vesicant11
- latex-free**94

N/A

10 mg/mL130

discard unused
portion130

syringe: 1.5 3.0


mg/mL in NS or
D5W130

24 h F, RT130

- cytotoxic3
- auxiliary label (for
syringe only):
Warning: FATAL if

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

27/33

DRUG & STRENGTH


(Storage Prior to Use,
Manufacturer, Presevative
Status)
no preservative130

B.C. CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART


Reconstitute
To Give:
Vial
Product
Product Stability
With:
Stability

0.5 2.0 mg/mL129,130

24 h F, RT130

50 mL* NS, D5W,


NS, D5NS,
Ringers, Ringers
Lactate130

Special
Precautions/Notes
given
intrathecally129
- vesicant11
- latex** content
not determined

* Suggested volume based on usual dose range and any concentration range of stability data
** Latex free means the product does not contain natural rubber latex in its packaging or is packaged as plastic (e.g., Polyamps) and glass ampoules 9

Note: As of January 2006, this table has been formulated based on a low risk classification when preparations are made according to current policies,
directives and standards of practice.

Explanatory Notes
Vial stability: Stability of solution after first puncture or reconstituted solution
Storage temperature: If information states same stability with refrigerator and room temperature storage, then bold refrigerated as preferred
Cytotoxic: hazardous (see Policy II-20 for more details).
Discard unused portion: Unused portion from single use vials are assumed to discarded at the end of the day.
If information states same stability with refrigerator and room temperature storage, then bold refrigerated as preferred (ie, to minimize growth of microorganisms).
State overfill known if the manufactuerer states overfill within acceptable limits is present.

PFL = protect from light


RT = room temperature
F = refrigerated
SWI = sterile water for injection
NS = normal saline
D5W = dextrose 5%
BWI = bascteriostatic water for injection
BC Cancer Agency Chemotherapy Preparation and Stability Chart
Activation Date: 2 March 2006
Revised Date: 29 August 2006

28/33

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

29/33

References
1. Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
2. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
3. National Institute for Occupational Safety and Health (NIOSH). Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Healthcare
Settings. Cincinnati, OH; 25 March 2004.
4. BC Cancer Agency. Systemic Therapy Policy III-20: Extravasation of Chemotherapy, Prevention and Management of. Vancouver, British Columbia: BC Cancer
Agency; 1 September 2006.
5. Schering AG. MabCampath Package Leaflet. Berlin, Germany; April 2002.
6. Berlex Canada Inc. Campath Drug Information. San Antonio, TX; Undated.
7. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004(18):484-90.
8. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for the treatment of fludarabine-refractory B-chronic lymphocytic leukemia (B-CLL) and Tprolymphocytic leukemia (T-PLL) with alemtuzumab (ULYALEM). Vancouver, British Columbia: BC Cancer Agency; 01 July 2006.
9. Latex allergy and parenteral products. In: Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists
Association; 2004. p. L93-5.
10. MedImmune Pharma B.V. Ethyol Package Insert. The Netherlands; 2003.
11. BC Cancer Agency. Systemic Therapy Policy III-20: Extravasation of Chemotherapy, Prevention and Management of. Vancouver, British Columbia: BC Cancer
Agency; 1 July 2006.
12. Emmanuelle Laflamme, B.Pharm. Personal communication. Medical Information Officer, Amsacrine, Pfizer. February 2005.
13. OPi SAS. Kidrolase Product Monograph. Laval, Quebec; 2003.
14. Robert Sarrazin, B Pharm. Personal communication. Consultant, OPi Inc. February 2005.
15. Rhone-Poulenc Rorer. Kidrolase Package Insert. Montreal; 2004.
16. BC Cancer Agency Lymphoma Tumour Group. BCCA Protocol summary for the treatment of Multiple Myeloma with Bortezomib. Vancouver: BC Cancer Agency;
UMYBORTEZ, 2005.
17. United States Pharmacopeia (USP). (797) Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: UPS Convention, Inc.; 2004.
18. Repchinsky C, editor. ImmuCyst monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005.
19. Organon Teknika Corporation. OncoTICE Product Monograph. Durham, North Carolina; January 1998.
20. Roche. Bevacizumab for injection, Summary product information. Mississauga; 2005.
21. Repchinsky C, editor. Blenoxane monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005.
22. Faulding (Canada) Inc. Bleomycin Product Monograph. Montreal, Quebec; 3 June 2002.
23. Sheila Ahmed. Personal communication Bleomycin. Regulatory Affairs Associate, Bleomycin, Mayne Pharma Canada 2004;July 2, 2004(Ref JUN-128-2004,).
24. Mayne Pharma (Canada) Inc. Latex-free products. Montreal, Quebec; Feb 8, 2005.
25. Millenium Pharmaceuticals Inc. Velcade product monograph. Cambridge, Massachusetts; May 2003.
26. Walker S, Milliken D, Law S. Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4C and room temperature (23C). Canadian Journal of
Hospital Pharmacy 2006;59 (Suppl 1):62.
27. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6
January 2006.
28. Janssen-Ortho Inc. Velcade product monograph. Toronto,Ontario; 18 April, 2006.
29. Orphan Medical I. Busulfex Package Insert. Flamborough, Ontario; August 1999.
30. Mayne Pharma (Canada) I. Carboplatin Package Insert. Montreal, QC; Undated.
BC Cancer Agency Chemotherapy Preparation and Stability Chart
Activation Date: 2 March 2006
Revised Date: 29 August 2006

30/33

31. Novopharm Limited. Vincristine product monograph. Scarbough, Canada; 1999.


32. Repchinsky C, editor. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
33. Bristol Laboratories of Canada. BiCNU Package Insert. Montreal, Canada; 2002.
34. Bristol-Myers Squibb. Quality Assurance. Montreal; February 2005.
35. Bristol-Myers Squibb. Erbitux(Cetuximab) Prescribing Information. 2004.
36. Mayne Pharma (Canada) Inc. Cisplatin Package Insert. Montreal, QC; Undated.
37. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
38. Repchinsky C, editor. Cisplatin CPhA monograph, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association;
2004.
39. Mayne Pharma (Canada) Inc. Cisplatin injection. Montreal, Quebec; 12 October, 2005.
40. Janssen-Ortho Inc. Leustatin Package Insert. North York, Ontario; 1998.
41. Oryx Pharmaceuticals Inc. Clasteon Product Monograph. Mississauga, Ontario; 25 November 2004.
42. Bristol-Myers Squibb Canada. Cytoxan Product Monograph. Montral Canada; 2004.
43. Baxter Corporation. Procytox Package Insert. Missisauga, Ontario; 1 October 2003.
44. Paul Agro. Personal communication. Medical Information, etoposide, Baxter. 12 July, 2006.
45. Baxter Corporation. Procytox Package Insert. Toronto, Ontario; 2004.
46. Faulding (Canada) Inc. Cytarabine Package Insert. Montreal, QC; Undated.
47. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. cytarabine injection - stability information 2005;# OCT-612005(October 17, 2005).
48. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. fluorouracil 2005;reference # FEB-43-2005(february 16, 2005).
49. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for solid tumours using intrathecal methotrexate and/or thiptepa and/or
cytarabine (MOIT). Vancouver, British Columbia: BC Cancer Agency; 2005.
50. BC Cancer Agency. Systemic Therapy Policy III-50: Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir.
Vancouver, British Columbia: BC Cancer Agency; 31 October 2002.
51. Yamina Chikhaoui, BPharm, PhD. Personal communication. Medical Information, Pfizer Canada. February 2005.
52. Mayne Pharma (Canada) Inc. Methotrexate Product Monograph. Montreal, QC; 2003.
53. Mayne Pharma (Canada) Inc. Dacarbazine Package Insert. Montreal, QC; 2004.
54. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. dacarbazine 2005;#FEB-14-2005(february 8, 2005).
55. Merck & CO. Inc. Cosmegen Package Insert. Whitehouse Station, NJ; December 2002.
56. Ernest Pregent. Personal Communication. Director Medical Services Merck Frosst, 2005;November 1, 2005.
57. Merck Frosst Canada. Personal communication. Medical Information, Dactinomycin, Merck Frosst Canada. February 2005.
58. Sam Jatoe. Personnal communication. Regulatory Affairs Associate, Daunorubicin, Novopharm. February 2005.
59. Pharmacia & Upjohn Inc. Zinecard Package Insert. Mississauga, Ontario; 2004.
60. Pharmacia & Upjohn Company. Zinecard: US Prescribing Information. Kalamazoo, MI; 2003 September.
61. Emmanuelle Laflamme, B.Pharm. Personal communication. Medical Information Officer, Dexrazoxane, Pfizer. February 2005.
62. Hoffmann-La Roche Limited. Rituxan Package Insert. Mississauga, Ontario; December 2002.
63. Aventis Pharma Inc. Taxotere Package Insert. Laval (Quebec) Canada; 2004.
64. Mayne Pharma (Canada) Inc. Doxorubicin Package Insert. Montreal, QC; Undated.
65. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, QC; 2002.
66. John Korontzis. Personal communication. Regulatory Affairs Associate, Doxorubicin, Mayne Pharma Canada. February 2005.
67. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996.
BC Cancer Agency Chemotherapy Preparation and Stability Chart
31/33
Activation Date: 2 March 2006
Revised Date: 29 August 2006

68. Schering Canada Inc. Caelyx Package Insert. Pointe-Claire, Quebec; September 2001.
69. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003.
70. Bristol Laboratories of Canada. Vepesid Package Insert. Montreal, Canada; March 2000.
71. Nicole Hojm, Kinda Karra. Personal communication. Medical Information, etoposide, Bristol-Myers Squibb. February 2005.
72. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000.
73. Berlex Canada Inc. Fludara Package Insert. Lachine, Quebec; December 1998.
74. Mayne Pharma (Canada) Inc. Fluorouracil Package Insert. Montreal, Quebec; Undated.
75. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy
1989;46(10):2036-40.
76. BC Cancer Agency. Guiding Principles for Chemotherapy Preparation Chart. Policy Number II-20 2005.
77. Eli Lilly Canada Inc. Gemzar Package Insert. Toronto, Ontario; 16 January 2002.
78. Marilyn Bain, BSc N. Personal communication. Sr Therapeutic Area Specialist Medical Information, Pemetrexed. October 21, 2005 2005.
79. Pharmacia & Upjohn Inc. Idamycin Package Insert. Mississauga, Ontario; July 1997.
80. BC Cancer Agency. revised Guiding Principles for Chemotherapy Preparation Chart. Policy Number II-30 2005.
81. Emmanuelle Laflamme, BPharm. Personal communication. Medical Information Officer, Idarubicin, Pfizer. February 2005.
82. Baxter Corporation. Ifex Package Insert. Toronto, Ontario; Undated.
83. Schering Canada Inc. Intron A Package Insert. Pointe-Claire, Quebec; January 2003.
84. Julie Lacasse, BScN RN. Personal communication. Associate Medical Information, Schering. February 2005.
85. Edward Kavalec, Schering Canada - Medical Services. Intron A (interferon alpha-2b). 2006.
86. Schering Canada. Intron A Product Monograph. Pointe Claire Quebec; December 2004.
87. Mayne Pharma (Canada) Inc. Iritnotecan Package Insert. Montreal, QC; 28 April 2005.
88. Beryl Chan. Personal communication. Mayne Pharma (Canada) Inc. Scientific Affairs Manager, Irinotecan. 2 February 2006.
89. Pharmacia Canada Inc. Camptosar Package Insert. Mississauga, Ontario; May 2002.
90. Faulding (Canada) Inc. Leucovorin Package Insert. Montreal, QC; Undated.
91. John Korontzis. Personal communication. Regulatory Affairs Associate, Leucovorin Calcium, Mayne Pharma Canada. February 2005.
92. Merck Frosst Canada & CO. Mustargen Package Insert. Kirkland, Quebec; 2 May 1994.
93. GlaxoSmithKline Inc. Alkeran Package Insert. Mississauga, Ontario; Montreal, Quebec; 2004.
94. GlaxoSmithKline. Summary of the rubber-containing components of GlaxoSmithKline products. February 2005.
95. Pharmaceutical Partners of Canada Inc. Mesna Package Insert. Richmond Hill, Ontario; November 2001.
96. John Korontzis. Personal communication. Regulatory Affairs Associate, Methotrexate, Mayne Pharma Canada. February 2005.
97. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Methotrexate, Vincristine, Mayne Pharma Canada. 14 March 2005.
98. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for treatment of leptomeningeal lymphoma or recurrent intracerebral lymphoma with high
dose methotrexate (LYHDMTXR). Vancouver, British Columbia: BC Cancer Agency; 1 June 2004.
99. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for treatment of meningeal disease (miscellaneous tumour origins) using high
dose methotrexate with leucovorin rescue (UMOHDMTX). Vancouver, British Columbia: BC Cancer Agency; 21 September 1999.
100. BC Cancer Agency Sarcoma Tumour Group. BCCA protocol summary for treatment of osteosarcoma using high dose methotrexate with leucovorin rescue
(OSHDMTX). Vancouver, British Columbia: BC Cancer Agency; 1 August 2000.
101. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for treatment of primary intracerebral lymphoma with high dose methotrexate
(LYHDMTXP). Vancouver, British Columbia: BC Cancer Agency; 1 June 2004.
102. Sam Jatoe. Personal communication. Regulatory Affairs Associate, Mitomycin, Novopharm. February 2005.
103. Bristol Laboratories of Canada. Mutamycin Package Insert. Montreal, Canada; 2000.
BC Cancer Agency Chemotherapy Preparation and Stability Chart
32/33
Activation Date: 2 March 2006
Revised Date: 29 August 2006

104. Wyeth Canada. Novantrone Package Insert. Montreal, Canada; October 2003.
105. Faulding (Canada) Inc. Mitoxantrone Package Insert. Montreal, Quebec; 2002.
106. Repchinsky C, editor. Sandostatin LAR monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005.
107. Vancouver Hospital and Health Sciences Centre Pharmacy Department. Octreotide. In: Parenteral drug therapy manual. Vancouver, BC; February 2002.
108. Sanofi-Synthelabo Oncology. Eloxatin Summary of Product Characteristics. Markham, Ontario; August 2001.
109. Sanofi-Synthelabo Inc. Eloxatin Prescribing Information. Bedford, OH; January 2004.
110. Mayne Pharma Plc. Oxaliplatin Mayne for injection. Royal Leamington Spa, Warwickshire, United Kingdom; 9 March 2006.
111. Sigmacon Lifesciences. Oxaliplatin for injection. North York, ON; January 2006.
112. Biolyse Pharma. Paclitaxel Package Insert. Ontario, Canada; November 2002.
113. Bristol-Myers Squibb Canada. Taxol Package Insert. Montreal, Canada; September 2002.
114. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
115. BC Cancer Agency Breast Tumour Group. BCCA protocol summary for treatment of acute bone pain secondary to breast cancer metastases using pamidronate or
IV clodronate (BRAVPAM). Vancouver, British Columbia: BC Cancer Agency; 1 May 2001.
116. Novartis Pharmaceuticals Corporation. Aredia Product Monograph. East Hanover, New Jersey,; 2003.
117. Eli Lilly Canada Inc. ALIMTA Product Monograph. Toronto, Ontario; 21 May 2004.
118. Axcan Pharma Inc. Photofrin Package Insert. Mont-Saint-Hilaire, Quebec; 2004.
119. Marie-Helene Doyon, B.Pharm., M.Sc. Personal communication. Medical Information Specialist, Porfimer, Axcan Pharma. 3 March 2005.
120. AstraZeneca. Tomudex Package Insert. Mississauga, Ontario; November 2001.
121. Pharmacia Canada Inc. Zanosar Package Insert. Mississauga, Ontario; March 2003.
122. Bedford Laboratories. Thiotepa Package Insert. Bedford, Ohio, U.S.A.; April 2001.
123. GlaxoSmithKline. Hycamtin Package Insert. Mississauga, Ontario; Montreal, Quebec; 2001.
124. Hoffmann-La Roche Limited. Herceptin Package Insert. Mississauga, Ontario; October 2002.
125. John Korontzis. Personal communication. Regulatory Affairs Associate, Mayne Pharma Canada. vinblastine 2005;#Feb-52-2005(february 17, 2005).
126. Repchinsky C, editor. Vinblastine CPhA monograph, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association;
2004.
127. Mayne Pharma (Canada) Inc. Vincristine Package Insert. Montreal, QC; Undated.
128. Trissel LA, Zhang Y, Cohen MR. The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hospital Pharmacy
2001;36(7):740-5.
129. GlaxoSmithKline Inc. Navelbine Package Insert. Mississauga, Ontario; Montreal, Quebec; Undated.
130. Mayne Pharma (Canada) Inc. Vinorelbine Product Monograph. Montreal, QC; Undated.

BC Cancer Agency Chemotherapy Preparation and Stability Chart


Activation Date: 2 March 2006
Revised Date: 29 August 2006

33/33